Guardant Health, Inc.

GH Healthcare Diagnostics & Research

Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.

Revenue
+36.1%
EPS
−25.7%
Free cash flow
+18.7%
Total debt
+34.8%

Quarter to September 2026, against a year earlier

144.36 9.07 −5.91%
Market cap
$20.6B
P/E
0.0×
Fwd P/E
−55.6×
Dividend yield
—
F-score
5/9
Altman Z
2.02
Beneish M
−2.78
Dividend safety
n/a

Guardant Health, Inc. 8-K filed Nov 3, 2026

Period ended Nov 2, 2026 · Filed · accepted 8:19 AM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov